Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORAL-I: 3D/2D Regimen in HCV Transplant Recipients
NCT01782495Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2013
- Primary completion
- Nov 2016
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label trial of ombitasvir, paritaprevir and dasabuvir in hepatitis C (HCV) (11 arms), sponsored by AbbVie Inc. Primary endpoint: Sustained Virologic Response 12 Weeks Post-treatment. Started Feb 2013; status: completed.
02
Drugs
ombitasvirparitaprevirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01782495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782495.